



# ANNUAL MEETING LIVE-STREAM SESSIONS GUIDE

Savannah, Georgia  
Tuesday, Oct. 15 - Friday, Oct. 18, 2024



Including a session by the Myasthenia Gravis Foundation of America.

# Virtual Option

If you're unable to join us in Savannah, Georgia, register for the virtual meeting option, which includes access to both the 2024 Annual Meeting Video Collection and an interactive livestream of featured sessions. During the live meeting, chat with other virtual attendees, connect with the live audience, and have questions answered by the presenters.

After the event, enjoy access to the 2024 Annual Meeting Video Collection, which includes recordings from most of the in-person meeting sessions, available in an easy-to-access, on-demand format. Registration gives you access to all content in the video collection indefinitely and the option to claim up to 97.5 CME/CEUs for 3 years.

## Virtual Meeting Stream + Collection

	Regular	Late
MEMBER	Aug. 1 - Sept. 15	Sept. 16 - Oct. 18
Physicians	\$530	\$605
Physicians-in-Training	\$370	\$445
Technologists, Collaborators, APPs, Researchers	\$370	\$445
TPP Physicians-in-Training	\$265	\$340
NONMEMBER		
Physicians	\$830	\$905
Physicians-in-Training	\$570	\$645
Technologists, Collaborators, APPs, Researchers	\$570	\$645

Register online today at [www.aanem.org/AnnualMeeting](http://www.aanem.org/AnnualMeeting). Contact [meeting@aanem.org](mailto:meeting@aanem.org) for assistance.



## Complimentary Meeting Registration for Medical Students

AANEM offers complimentary membership and meeting registration for all medical students.

Medical students are encouraged to register at no cost to experience valuable opportunities to learn with peers, program directors, and leaders in neurology and PM&R; gain knowledge from sessions at the AANEM Annual Meeting.

Contact [membership@aanem.org](mailto:membership@aanem.org) to learn more.

**08:00 AM - 09:30 AM**

Eastern Standard Time

UTC/EST -5 hours

**Inflammatory Myopathies**

Utilize myositis specific autoantibodies and muscle pathology in diagnosing patients with suspected inflammatory myopathies; diagnosis and treat patients with various subtypes; and recognize the importance of multidisciplinary approaches in management of these patients.

**1.50**  
CME/CEU

Didem Saygin, MD | Grayson Beecher, MD | Teerin Liewluck, MD | Bhaskar Roy, MBBS

**08:00 AM - 12:00 PM**

Eastern Standard Time

UTC/EST -5 hours

**MGFA Session**

The Myasthenia Gravis Foundation of America (MGFA) Medical & Scientific Advisory Council (MSAC) invites clinical and scientific experts to share current and prospective peer-reviewed research focused on myasthenia gravis (MG) and related disorders of the NMJ. The scientific session will include presentations highlighting the latest advancements in our understanding of MG etiology, immunopathology, therapeutic developments, and management. Program and speakers subject to change.

Julia Manasson, MD | Jonathan B. Strober, MD | Aiden Haghighi, MD | Vera Kiyasova, MD, PhD | Samantha Masterson, President and CEO, MGFA | Anna R. Punga, MD, PhD | | Huahua Zhong, MD | Yingkai (Kevin) Li, MD | Patricia Sikorski, PhD | Diana Castro, MD | Neelam Goyal, MD | Richard J. Nowak, MD, MS | Mamatha Pasnoor, MD | Christopher Evans, MD | Poster Session | Faye Yu, BS | Tuan H. Vu, MD | James F. Howard, MD | Kevin O'Connor, PhD | Martin Skov, PhD | Alexander Fay, MD, PhD

No CME/CEU

**08:00 AM - 09:30 AM**

Eastern Standard Time

UTC/EST -5 hours

**Navigating Through the Available Therapies for Duchenne: How Do You Choose?**

Review the current FDA approved therapies for DMD and discuss the benefits and limitations of each; recognize the role of each in the general landscape of treatment; and create a framework for thinking through how to apply these therapies to real world patients.

**1.50**  
CME/CEU

Craig M. Zaidman, MD | Nancy L. Kuntz, MD

**08:00 AM - 09:30 AM**

Eastern Standard Time

UTC/EST -5 hours

**Peripheral Nerve and Muscle Pathology**

Recognize clinical situations to order nerve and muscle biopsies; correlate nerve and muscle pathology with EMG and imaging abnormalities; and review important nerve and muscle biopsies pathology findings for UCNS board examination.

**1.50**  
CME/CEU

Sarah E. Berini, MD | Aziz Shaibani, MD

**10:00 AM - 11:30 AM**

Eastern Standard Time

UTC/EST -5 hours

**Add-On Therapy for SMA**

Explore the effect of myostatin inhibitors on patients with SMA; examine the state of various antisense oligonucleotide therapies; and survey other small molecule therapies in early studies as well as "add-on" intrathecal gene therapy for older patients with SMA.

**1.50**  
CME/CEU

Meeta Cardon, MD | Jenna Klotz, MD | Ashley N. Stanley-Copeland, MD

**10:00 AM - 11:30 AM**

Eastern Standard Time

UTC/EST -5 hours

**Pathologies in NMUS: Common and Uncommon Findings**

Describe a variety of case-based examples of pathologies seen using NMUS. Emphasis will be on practical applications covering mononeuropathies, polyneuropathy and muscle diseases, and anatomical variations and other red herrings.

**1.50**  
CME/CEU

Mary Hopfinger, NP | Craig M. Zaidman, MD | David C. Preston, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Periprocedural and Peripartum Nerve Injuries

Identify the spectrum of peripheral nerve injuries that can develop during surgical procedures (including orthopedic, cardiothoracic) and in the context of regional anesthesia (single shot and take-home catheters) during pregnancy and the peripartum period, including injuries related to pregnancy, childbirth, epidural anesthesia, breastfeeding, and gynecologic procedures; discuss the pertinent anatomy of commonly and uncommonly affected nerves, and describe the symptoms of focal neuropathies; describe collaborative treatment with surgeons and OB/GYN; explain treatment options including nerve transfer surgery and nerve release surgery; distinguish models for collaborative peripheral nerve team for acute referral, evaluation, and treatment; and summarize key medicolegal aspects and apply tips for documentation and patient communication.

1.50  
CME/CEU

Raymond Chou, MD | Sarada Sakamuri, MD |  
Lawrence R. Robinson, MD

11:45 AM -  
12:45 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Voxmedia LLC - Industry Forum

### Improving Outcomes of Patients With Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Transthyretin amyloid polyneuropathy (ATTR-PN) is often unrecognized, misdiagnosed and either treated inappropriately or undertreated owing to the rarity of the disease. There have been substantial advances in the understanding of ATTR-PN which have led to enhanced diagnostic approaches with genetic testing, along with several recent targeted treatment approvals. Clinicians would benefit from a better understanding of the signs, symptoms, heritability, and other factors that indicate possible ATTR-PN because organs like the heart, eyes, kidney and gastrointestinal system can be involved in addition to the peripheral and central nervous system. Clinicians also would benefit from expert guidance regarding the diagnostic process and a description of current treatment options for patients with ATTR-PN. In this program, ATTR-PN experts (chair Dr. Morie Gertz, and faculty members Dr. Amanda Peltier and Dr. Michelle Mauermann) will present, through lectures and “realworld” case studies, current evidence and best practices for management of ATTR-PN.

#### Presenters:

Morie A. Gertz, MD  
Michelle L. Mauermann, MD  
Amanda Peltier, MD, MS

- Describe strategies for screening and diagnosing ATTR-PN
- Explain the importance of genetic testing in patients suspected of or at risk for ATTR-PN
- Discuss the effectiveness of currently available therapies for ATTR-PN

This accredited CME session is provided by Voxmedia LLC from an educational grant provided by AstraZeneca Pharmaceuticals. Voxmedia, LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit. This activity is not part of the official scientific program of AANEM.

No CME/CEU



## Explore Learning Resources

Visit AANEM's Learning Center for educational products, including instructional videos and interactive courses.



01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Getting Started With US in Clinical Practice

Develop a strategy for implementing US in one's own clinical practice; discuss features of various types of US machines and what may be important clinically to consider before purchasing an US; describe the criteria for appropriate and complete clinical documentation of diagnostic US evaluations including examples of comprehensive reports; and define relevant billing codes.

1.50  
CME/CEU

Nirmal Andrapalliyal, MD | Chelsea Shugars, MD | Vanessa Baute Penry, MD

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Muscle US: Quantitative Assessment and Patterns of Muscle Involvement

Identify US findings characteristic of myopathic and neurogenic disorders; describe methods for quantifying skeletal muscle thickness and echo intensity; recognize the utility of quantitative muscle US for diagnosis and disease monitoring; and apply quantitative muscle US techniques in evaluating patients with NMDs.

1.50  
CME/CEU

James B. Meiling, DO | Adam D. Comer, MD

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Pipeline Treatments for CMT

Identify the main strategies and challenges to treating genetic neuropathies; discuss novel and emerging small molecule treatment candidates for genetic neuropathies; and discuss emerging genetic therapies for different inherited neuropathies.

1.50  
CME/CEU

Bipasha Mukherjee-Clavin, MD, PhD | Mario Saporta, MD, PhD

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## When Something Doesn't Look Right: A Case-based Approach to NCS Artifacts and Anomalies

Recognize and prevent technical anomalies frequently encountered during NCS; identify pitfalls in NCS, including the effects of understimulation and overstimulation on CMAPs and SNAPs, the impact of limb positioning on ulnar NCS, and how misplaced electrodes affect latency and amplitude calculations; manage frequently encountered electrical artifacts; identify the effects of sweep speed and sensitivity on latency of responses; recognize anomalous innervations; and understand the impact of temperature, limb movement, and submaximal stimulation on RNS testing.

1.50  
CME/CEU

Peter P. Pacut, MD | Isabel V. Narvaez Correa, MD | Kelly G. Gwathmey, MD

03:30 PM -  
05:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Plenary 1: Confluence of Two Pipelines

Identify key ethical concerns and challenges related to distributive justice arising from high drug prices; evaluate the potential impact of high drug prices and other structural factors on healthcare delivery; and discuss the demands on physician time, including issues related to burnout, healthcare financing, and potential policy solutions to address these ethical and structural challenges in healthcare.

Note: AANEM's Annual Business Meeting will be held at the beginning of this session. Fellow, Active, and Research members will have the opportunity to vote and are encouraged to attend.

2.00  
CME/CEU

Amy Tsou, MD, PhD | Earl J. Craig, MD | Dianna Quan, MD



08:00 AM - 09:30 AM	<b>Basics of NCS and Needle EMG - Part 1</b>	08:00 AM - 09:30 AM	<b>Update on Pediatric NMJ Disorders</b>
Eastern Standard Time	Articulate the basic concepts underlying nerve conduction and approach to the study; conduct and interpret NCSs in the upper and lower extremities and identify anomalous innervations; utilize specialized studies including RNS, cranial nerve studies, and blink reflex; apply needle EMG for the diagnosis of NMDs; and recognize common pitfalls and explain technical factors and safety considerations affecting the study.	Eastern Standard Time	Identify the clinical presentation of NMJ disorders; discuss genetic testing considerations; describe appropriate EDX testing; and explain management principles in pediatric patients.
UTC/EST -5 hours		UTC/EST -5 hours	
1.50 CME/CEU	Kelly G. Gwathmey, MD   Mohammad K. Salajegheh, MD	1.50 CME/CEU	Sumit Verma, MD   Ai Sakonju, MD   Matthew Ginsberg, MD
08:00 AM - 09:30 AM	<b>EDX and US Evaluation of Generalized Peripheral Neuropathies - Part 1</b>	10:00 AM - 11:30 AM	<b>Basics of NCS and Needle EMG - Part 2</b>
Eastern Standard Time	Identify the sonographic appearance of nerves and muscles and surrounding anatomic structures frequency used in the identification and assessment of generalized peripheral neuropathies; review scanning techniques for image optimization; and describe the EDX approach to evaluate and qualify generalized peripheral neuropathies and other disorders within the differential diagnosis.	Eastern Standard Time	Articulate the basic concepts underlying nerve conduction and approach to the study; conduct and interpret NCSs in the upper and lower extremities and identify anomalous innervations; utilize specialized studies including RNS, cranial nerve studies, and blink reflex; apply needle EMG for the diagnosis of NMDs; and recognize common pitfalls and explain technical factors and safety considerations affecting the study.
UTC/EST -5 hours		UTC/EST -5 hours	
1.50 CME/CEU	Jeffrey A. Strakowski, MD   Devon I. Rubin, MD	1.50 CME/CEU	Joseph M. Choi, MD   Aaron Izenberg, MD
08:00 AM - 09:30 AM	<b>Paradigm Clashes: Debate and Exploration in Choosing Traditional vs Novel Immunotherapeutics for MG</b>	10:00 AM - 11:30 AM	<b>EDX and US Evaluation of Generalized Peripheral Neuropathies - Part 2</b>
Eastern Standard Time	Discuss advantages and pitfalls of traditional immunotherapies for MG such as corticosteroid, corticosteroid sparing agents, and thymectomy; describe advantages and pitfalls of novel immunotherapies such as B cell depleting agents, complement and FcRn inhibitors; and apply an individualized and cost-effective approach in managing patients.	Eastern Standard Time	Recognize the scientific basis for using NMUS for evaluating generalized peripheral neuropathies; and review the integration of both NMUS and EDX and the relative strengths and weaknesses of both. Case studies with also be used with this session.
UTC/EST -5 hours		UTC/EST -5 hours	
1.50 CME/CEU	Benjamin Claytor, MD   Neelam Goyal, MD   Michael K. Hehir, MD   Yuebing Li, MD, PhD   Amanda C. Guidon, MD	1.50 CME/CEU	Michael S. Cartwright, MD   Jeffrey A. Strakowski, MD
		10:00 AM - 11:30 AM	<b>SFEMG - Principles, Practice, and Pitfalls</b>
		Eastern Standard Time	Review the principles underlying the measurement of jitter and fiber density with SFEMG electrodes; distinguish the differences between recordings made with SFEMG and concentric needle electrode; and recognize common artifacts encountered during voluntary muscle activation and axonal stimulation.
		UTC/EST -5 hours	
		1.50 CME/CEU	Vern C. Juel, MD   Amanda C. Guidon, MD   Donald B. Sanders, MD

# Wednesday | Oct. 16

10:00 AM -  
11:30 AM

## Unicorns and Zebras: Unusual Pediatric NM Cases

Eastern  
Standard  
Time

Discuss diagnostic odysseys in pediatric NM conditions, emphasizing the confluence of clinical acumen, diagnostic studies including imaging and genetics.

1.50  
CME/CEU

Mathula Thangarajh, MD, PhD | Pitchamol Vilaisaktipakorn, MD

11:45 AM -  
12:45 PM

## CME Institute of Physicians Postgraduate Press Inc. - Industry Forum

Eastern  
Standard  
Time

Assessing Progress in FSHD Treatment Options: Unraveling Challenges and Measuring Outcomes

UTC/EST  
-5 hours

Join Dr. Leo Wang and Dr. Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD), covering its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don't miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.

Upon completion of this session, participants will be able to:

- Evaluate the use of RWS as an outcome measure for FSHD clinical trials to measure disease progression, impact on ADLs, and effect of therapy
- Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

This accredited CME session is provided by CME Institute of Physicians Postgraduate Press Inc. from an educational grant provided by Fulcrum Therapeutics. CME Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit. This activity is not part of the official scientific program of AANEM.

No CME/CEU

## AANEM UltraEMG

March 12 to 15, 2025  
Fort Lauderdale, Florida



01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Cardiac and Pulmonary Manifestations of NMDs

Recognize, diagnose, and treat common cardiac and pulmonary complications seen in patients with various NMDs; and discuss how to work with colleagues and pulmonology to provide better care.

1.50  
CME/CEU

Michael K. Hehir, MD | Nicholas J. Silvestri, MD

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Gene Therapy, CRISPR, and Other Genetic Strategies for NMDs

Identify the current approaches to treating genetic NMDs; discuss novel and emerging approaches to treating genetic NMDs; and discuss the potential adverse effects of approved and emerging genetic therapies in treating genetic NMDs.

1.50  
CME/CEU

Melissa Spencer, PhD | Stefan Nicolau, MD | Perry B. Shieh, MD, PhD

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Optimizing the Role of APPs in NM Practice

Discuss the APP profession and MD/APP shared practice models that maximize productivity, promote retention, and allow APPs to practice at the top of their license; create an on-the-job training plan for APPs entering neurologic practice; determine strategies for tracking APPs' clinical competency in real-time to match their responsibilities with their skills and strengths; provide testimony for APP utilization in a comprehensive multidisciplinary ALS clinic and discuss additional APP roles in education, leadership, research, advocacy, and philanthropy; and create a team-based approach to improve patient experience, increase access to NM care, and reduce provider burnout.

1.50  
CME/CEU

Christopher Doughty, MD | Maggie Naclerio, PA-C | Darlene E. Sawicki, MSN, NP-BC | Deena M. Rodney, APRN

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## The Use of Muscle MRI in the Diagnosis and Treatment of Myopathies

Describe how to use muscle MRI in the diagnosis of acquired and inherited myopathies; define the role of muscle MRI in treatment monitoring of patients with immune mediated myopathies; and highlight the use of quantitative muscle MRI as a surrogate measure in myopathy clinical trials.

1.50  
CME/CEU

Pedro Machado, MD | Julie Paik, MD | Elie Naddaf, MD

03:30 PM -  
05:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Plenary 2: Confluence of Two Pipelines

Identify and implement innovative educational strategies, such as the flipped classroom, micro-educational opportunities, online education, and the use of humor and games, to enhance recruitment and training, and discuss the importance of self-assessment and certification examinations in ensuring practitioner competence and maintaining high standards of patient care.

Understand the role of "augmented" intelligence in enhancing the synergy between artificial and human intelligence and its potential advancements in clinical care, research, and education and evaluate and implement strategic, ethical, and responsible AI integration in NM and EDX medicine to improve patient outcomes and foster innovation.

2.00  
CME/CEU

John A. Morren, MD | Earl J. Craig, MD | Dianna Quan, MD | Lawrence R. Robinson, MD



08:00 AM -  
09:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## ALS an Update in Diagnosis, Pathophysiology, and Treatment

Diagnose ALS and identify ALS mimickers (focused on early diagnosis); review the latest development of ALS pathophysiology; summarize the importance of multidisciplinary care; and discuss the therapeutic landscape and clinical trials.

1.50  
CME/CEU

Suma Babu, MBBS, MPH | Senda Ajroud-Driss, MD | Ximena Arcila-Londono, MD | Colin K. Franz, MD, PhD

08:00 AM -  
09:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Clinical Trials Round Up/Research Updates

Discuss the types of approved genetically targeted therapies for SMA and DMD and data supporting approval; review the DMD treatment landscape beyond genetically-targeted therapies, including corticosteroids, givinostat and other treatments still under investigation; discuss the treatment approach for congenital myopathies and congenital myasthenic syndromes, including data from the halted MTM1 gene therapy trial; review the diagnosis and management of pediatric MG, highlighting seronegative MG and treatment of refractory MG in children; review the mechanism of myostatin inhibition, current ongoing clinical trials, translational research, and potential application in multiple pediatric NM conditions; recognize the utility and relevance of skeletal muscle needle biopsy post genetic therapies; review the process of RNA/transcriptomic analysis of skeletal muscle; and describe cellular and molecular changes in dystrophic skeletal muscle; and review the process of assessing durability of skeletal muscle transgene expression.

1.50  
CME/CEU

Stanley Nelson, MD | Michelle Allen-Sharpley, MD, PhD | Emmanuelle Tiongson, MD | Alexander Fay, MD, PhD

08:00 AM -  
09:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Hot Topics in NM Literature - Part 1

Appraise several impactful findings in NM literature over the past year; recognize the clinical value of these studies and their impact to NM patients (EDX and sonographic methods, hereditary and acquired myopathy evaluation, peripheral neuropathy testing and treatment, motor neuron disease understanding and NMJ disorder advancements); describe hot topics and groundbreaking work in these areas of NM medicine; and integrate emerging knowledge into clinical practice.

1.50  
CME/CEU

Colin C. Quinn, MD | Miriam L. Freimer, MD | Ruple S. Laughlin, MD

08:00 AM -  
09:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## MSK Mimics of Radiculopathy

Discuss a broad differential in patients presenting with possible radicular pain, that includes MSK mimics of radiculopathy.

1.50  
CME/CEU

Dale Colorado, DO, MPH | E. Ali Bateman, MD | Lawrence R. Robinson, MD | Christian D. Fortin, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## EDX NM Challenging Cases - Part 1

Apply and refine the process of diagnostic formulation in NM medicine and clinical EMG and improve patient care by presenting and discussing challenging cases. This session relies on AANEM members to provide challenging cases.

1.50  
CME/CEU

Bashar Katirji, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Hot Topics in NM Literature - Part 2

Appraise several impactful findings in NM literature over the past year; recognize the clinical value of these studies and their impact to NM patients (EDX and sonographic methods, hereditary and acquired myopathy evaluation, peripheral neuropathy testing and treatment, motor neuron disease understanding and NMJ disorder advancements); describe hot topics and groundbreaking work in these areas of NM medicine; and integrate emerging knowledge into clinical practice.

1.50  
CME/CEU

Elie Naddaf, MD | Noah A. Kolb, MD | Ruple S. Laughlin, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## MSK US for MSK Conditions Encountered During an NM Evaluation

Identify common MSK problems that can confound symptoms and NM evaluation using high frequency US; discuss MSK dilemmas facing NM specialists; and describe the techniques for identifying confounding concomitant MSK comorbidities. The session will be interactive and include live discussion.

1.50  
CME/CEU

Craig M. Zaidman, MD | Jeffrey A. Strakowski, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## Pediatric EMG Cases

Discuss the role of EMG in the pediatric population and give different examples of cases in which it contributed substantially to diagnosis and/or management.

1.50  
CME/CEU

Gabrielle Nguyen, MD | Alexandra Bonner, MD | Hoda Z. Abdel-Hamid, MD | Kathryn A. Mosher, MD | Matthew Ginsberg, MD

11:45 AM -  
12:45 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

## PVI, PeerView Institute for Medical Education - Industry Forum

Steering Away From Steroids in Myasthenia Gravis Management: The Role of FcRn Inhibitors in the Current Treatment Paradigm

Although corticosteroids have long been a mainstay of generalized myasthenia gravis (gMG) management, their adverse effects have spurred the search for better treatments, such as neonatal Fc receptor (FcRn) inhibitors. FcRn inhibitors demonstrate rapid therapeutic response and better safety and tolerability compared with conventional treatments, and two medications in this class—efgartigimod and rozanolixizumab—are approved for gMG in the United States.

To learn more about this virtual CME symposium and to pre-register, visit: [PeerView.com/2024gMG-Live](https://www.peerview.com/2024gMG-Live).

Upon completion of this activity, participants should be better able to:

- Implement strategies to monitor for corticosteroid-related AEs in patients with gMG
- Assess the efficacy of FcRn inhibitors in achieving steroid-sparing treatment goals for individuals with gMG based on quality of life, healthcare resource utilization, and real-world data
- Integrate FcRn inhibitors into tailored treatment plans for patients with gMG, leveraging the potential of these agents to mitigate glucocorticoid-related AEs and improve overall outcomes

Presenters:

James F. Howard Jr., MD  
Nicholas J. Silvestri, MD

This accredited CME session is provided by PVI, PeerView Institute for Medical Education from an educational grant provided by argenx US, Inc. PeerView designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit. This activity is not part of the official scientific program of AANEM.

No CME/CEU

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

1.50  
CME/CEU

## EDX NM Challenging Cases - Part 2

Apply and refine the process of diagnostic formulation in NM medicine and clinical EMG and improve patient care by presenting and discussing challenging cases. This session relies on AANEM members to provide challenging cases.

**Bashar Katirji, MD**

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

1.50  
CME/CEU

## Harnessing the Power of AI: Exploring AI Tools

Increase proficiency and competence regarding AI resources including ChatGPT and Consensus and leverage these AI tools to enhance clinical practice, research, and educational work.

**John A. Morren, MD**

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

1.50  
CME/CEU

## MRI and US Imaging of Brachial Plexus and Peripheral Nerve in a Multidisciplinary Clinic

Discuss when to order MRI or US for patients with a brachial plexus or peripheral nerve injury; review how imaging studies are used to help localize lesions and determine if there is an obstruction pressing against the nerve. i.e. tumor; and review case studies to demonstrate how important these imaging studies are in connection with the physical exam and EMG studies.

**Hemant Parmar, MD | Teresa Spiegelberg, CNCT, R.NCS.T., R.EEGT | Ann A. Little, MD**

01:00 PM -  
02:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

1.50  
CME/CEU

## US Evaluation of the Tibial Nerve at the Tarsal Tunnel

Develop a systemic approach to using US to assess tibial neuropathy at the tarsal tunnel; and discuss the relative strengths and limitations of EDX and NMUS. Case examples of varying sources of neuropathy in this location will be discussed.

**Jeffrey A. Strakowski, MD**

03:30 PM -  
05:30 PM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

2.00  
CME/CEU

## Plenary 3: Confluence of Two Pipelines

Describe electrodiagnosis in the acute care setting with an emphasis on the role of the interprofessional team and professional networks in helping patients with NMDs receive the highest level of care.

Discuss the lessons learned from the development of the VA ALS system of care; explain how ALS care must evolve in the 21st century to adapt to the rapidly changing therapeutic landscape; identify strategies to optimize the work of the interprofessional NM care team to best support patients and caregivers and analyze the implications for the future of NM care.

Supported by an educational Grant Provided by Mitsubishi Tanabe Pharma America, Inc.

Achievement Awards presentation will take place at the beginning of the Plenary.

**Marcos Vinícius Oliveira Marques, MD | James Dines | Faye C. Tan, MD | Ileana Howard, MD | Andrea J. Boon, MD | John W. Norbury, MD | Dianna Quan, MD**

08:00 AM - 09:30 AM	<b>Myalgia and Muscle Stiffness: Approach and Management</b>
Eastern Standard Time	Classify and identify causes of muscle pain and stiffness; diagnose and manage various forms of myotonic disorders; identify and manage stiff person syndrome and peripheral nerve hyperexcitability; and evaluate for and treat myofascial pain syndrome and fibromyalgia.
UTC/EST -5 hours	
1.50 CME/CEU	Mohammad K. Salajegheh, MD   Erik R. Ensrud, MD   Goran Rakocevic, MD
08:00 AM - 09:30 AM	<b>NM Complications of Cancer Care</b>
Eastern Standard Time	Familiarize participants with the common NM complications of cancer care, including chemotherapy induced peripheral neuropathy and NM immune related adverse events such as MG and Myositis; and review diagnosis, prevention, treatment, and use of current guidelines for these disorders. The session will conclude with real world cases to provide examples of how these principles work in practice.
UTC/EST -5 hours	
1.50 CME/CEU	Noah A. Kolb, MD   Brendan L. McNeish, MD
08:00 AM - 09:30 AM	<b>Small Nerve Fiber Dysfunction in Children and Adolescents - When NCSs Don't Identify the Problem</b>
Eastern Standard Time	Recognize the symptoms and signs of small nerve fiber dysfunction in children and adolescents; identify appropriate tests for evaluation and confirmation of diagnosis; and recognize how problems with neuropathic pain and autonomic dysfunction will benefit from clinical, physiologic and anatomic test approaches. There will be an emphasis on the least invasive, best tolerated testing modalities.
UTC/EST -5 hours	
1.50 CME/CEU	Bridget McGowan, MD   Nancy L. Kuntz, MD   Monika Krzesniak-Swinarska, MD

08:00 AM - 09:30 AM	<b>US for Nerve Injury With a Focus on Surgical Planning</b>
Eastern Standard Time	Describe basic pathophysiology of peripheral nerve injury secondary to trauma and common US correlations; analyze individual cases to determine how US findings in nerve trauma and determine how US findings may change the patient's diagnosis and/or management, especially with regard to surgical planning; and collaborate effectively with surgical colleagues in treatment planning for patients with nerve injury.
UTC/EST -5 hours	
1.50 CME/CEU	Yusha Katie Liu, MD, PhD   Sarah M. Smith, MD   Sarada Sakamuri, MD
10:00 AM - 11:30 AM	<b>Case-Based Approach to US for Respiratory Management in NMD</b>
Eastern Standard Time	Describe NMUS techniques used to assess diaphragm function in NMDs; recognize the utility of diaphragm US imaging in assessing respiratory impairment in NMDs including when traditional pulmonary function measures are impeded due to bulbar involvement and natural progression of NMD; describe NMUS techniques used to assess diaphragm function in NMD; and discuss the use of serial US for prediction of disease progression and NIV initiation in NMD.
UTC/EST -5 hours	
1.50 CME/CEU	Grayson Beecher, MD   Andrea J. Boon, MD   Colin K. Franz, MD, PhD
10:00 AM - 11:30 AM	<b>Current Treatment of ALS: Disease Modifying Therapies, Symptomatic Medication, and Rehab Management</b>
Eastern Standard Time	Discuss the considerations, utility, and limitations related to the use of disease modifying therapies approved for ALS; identify symptomatic medications for complications, including sialorrhea, muscles cramps, and pseudobulbar affect, and explain how these can significantly improve quality of life; and outline the role of rehabilitation medicine in addressing impaired function and mobility.
UTC/EST -5 hours	
1.50 CME/CEU	Nassim Rad, MD   Bjorn E. Oskarsson, MD   Michael D. Weiss, MD



Friday | Oct. 18

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

### **Diagnosis and Treatment: Breakthrough Genetic Testing for NMDs**

Recognize how current testing platforms lead to the latest advances in population genomic-driven drug discovery; apply the principles of genetic diagnosis/interpretation in the NM clinic and discuss the transition of novel molecular therapeutics into practice; and review ongoing technological advances and clinical trial data utilizing gene therapies for NMD to identify therapeutics that are likely to be in the clinic within the next 5 years.

1.50  
CME/CEU

Nicolas N. Madigan, MBBCh, PhD | Zhiyv N. Niu, PhD | Jennifer M. Martinez-Thompson, MD

10:00 AM -  
11:30 AM

Eastern  
Standard  
Time

UTC/EST  
-5 hours

### **NMUS in Children**

Describe the unique aspects of using NMUS when assessing children and how US can be combined with EDX in this population.

1.50  
CME/CEU

Michael S. Cartwright, MD | Craig M. Zaidman, MD



Take your career to new heights with the help of the AANEM Career Center.

- Search hundreds of jobs
- Get personalized email job alerts
- Contract negotiation and CV/resume assistance

Find a new job today.  
[www.healthcareers.com/aanem/search-jobs](http://www.healthcareers.com/aanem/search-jobs)





SAVE THE DATE  
2025 AANEM Annual Meeting  
San Francisco, California | Oct. 29 - Nov. 1

